Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback